HCV / Hepatitis

Alcohol Awareness Month highlights the need for action amidst the alcohol crisis in the US.

Clinicians discuss screening and treatment approaches for the disease.

Insights from a CDC study on challenges and research direction in pediatric hepatitis.

Bulevirtide's key role in blocking hepatitis virus entry.

Insights on Sofosbuvir levels in pregnant women.

The evolution of treatment for hepatitis C virus during the past 15 years has been astounding, and we now are able to talk about how HCV could be eliminated.

Here is a review of an opportunistic treatment approach to HCV infection in this patient population in a European study and some of the potential challenges in applying it in the United States.

Wireless test kit transforms screening efforts towards combating the virus.

New analysis indicates that children treated at 3 years of age for perinatally acquired HCV will live longer, with less liver morbidity and lower health care costs than if treated at 6 years of age.

A vaccine targeting chronic HBV has entered its first human trial; Saskia Popescu, PhD, on the importance of pandemic preparedness and global health security; a successful phase 2 trial for a C diff treatment leads to the next phase; and more stories this week from Contagion.

This year at the Conference on Retroviruses and Opportunistic Infections (CROI), Lenacapavir shows virological suppression, Remdesivir reduces long covid risks, Bulevirtide benefits chronic HBV, HIV treatment enhances outcomes, vaginal ring or oral pre-exposure prophylaxis safe for HIV prevention throughout pregnancy.

Vaccine designed to confront chronic HBV entering its first human clinical trial.

Insights from CROI on the HepB-CpG vaccine trial.

Insights from phase 3 study evaluating bulevirtide efficacy in coinfections.

Study presented at CROI 2024 reveals chronic hepatitis B virus (HBV) infection heightens COVID-19 severity as vaccination reduces mortality and ICU demands in co-infected individuals.

In thinking about the international and national public health campaigns to eliminate hepatitis, is general awareness of the disease enough to motivate treatment-hesitant hepatitis patients to accept clinical care, or does there need to be a greater commitment beyond that?

This week, why measles and vibrio vulnificus infections are seeing outbreaks and increases in incidence rates; a medical association recommends fecal microbiota-based therapies for recurrent or severe C difficile; and an antiviral reduced a median time-to-symptom resolution.

Study exposes the adherence gap in HCV direct-acting antiviral therapy among people who inject drugs.

Shortage in hepatitis b virus (HBV) clinical trials within the WHO African region.

The federal government is working to provide greater access to testing and treatment.

Accessibility to direct-acting antivirals affecting low and middle-income countries.

Results highlight the benefit of achieving sustained virological response with DAAs for decreasing patients’ risk of carotid atherosclerosis and peripheral artery disease, especially among those with severe fibrosis.

Study reveals HEV adaptation during treatment.

GSK’s bepirovirsen received this designation, and the company has its sights on the therapy potentially providing a functional cure for the millions of people around the world who are affected by this form of viral hepatitis.

This month is a time to reflect on the past, but understand there remains issues that need to be addressed today.

HCV seroprevalence and antigen positivity were both low, suggesting universal birth cohort screening may not be necessary or cost-effective.

This week, a study advocates enhancing hospital cleaning protocols to halt healthcare-associated infections; integrating HCV testing and antivirals in prisons to cut transmission of the disease; FDA announces listeria outbreak that leads to deaths and hospitalizations across 11 US states; CDC makes advances in foodborne outbreak detection via genome sequencing; and new data about the self-amplifying mRNA vaccine, ARCT-154.

Combating hepatitis C (HCV) transmission through integrated testing and enhanced use of direct-acting antivirals within the prison system can reduce incidence rates.

Sustained virologic response (SVR) and sociodemographic factors were found to be associated with long-term improvements in health-related quality of life in patients with hepatitis C (HCV).

This week, a measles outbreak spans multiple US states and the CDC highlights a rise in syphilis incidents. Fatalities from Group A strep infections have doubled since last year in Canada, and people who inject drugs are at higher risk for hepatitis C and HIV. Investigators are also tracking incident rates over time post-COVID-19 pandemic.